Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders
详细信息 查看全文
- 作者：Katelyn J. Carey ; M.P.H.a ; kjcarey@bu.edu" class="auth_mail" title="E-mail the corresponding author ; Wei Huang ; M.P.H. ; Ph.D.b ; weih@bu.edu" class="auth_mail" title="E-mail the corresponding author ; Benjamin P. Linas ; M.D. ; M.P.H.a ; b ; c ; Benjamin.linas@bmc.org" class="auth_mail" title="E-mail the corresponding author ; Judith I. Tsui ; M.D. ; M.P.H.c ; 1 ; tsuij@uw.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ab ; antibody ; ALT ; alanine transaminase ; AST ; aspartate transaminase ; BMC ; Boston Medical Center ; DAA ; directly acting antivirals ; EMR ; electronic medical record ; ETR ; end-treatment response ; FDA ; Food and Drug Administration ; FIB-4 ; fibrosis-4 ; HIPAA ; Health Insurance Portability and Accountability ; HCV ; Hepatitis C virus ; HIV ; human immunodeficiency virus ; ICD ; International Classification of Diseases ; ID ; infectious disease ; OBOT ; office-based opioid therapy ; OAT ; opioid agonist treatment ; PT
- 刊名：Journal of Substance Abuse Treatment
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：66
- 期：Complete
- 页码：54-59
- 全文大小：327 K
文摘
- •
The HCV prevalence was 48% among these buprenorphine treated patients.
- •
Only 2% of patients engaged in a buprenorphine program received HCV treatment.
- •
The OBOT care model could provide integrated substance abuse and HCV treatment.